2. Academic Validation
  3. Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy

Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy

  • Bioconjug Chem. 2016 Dec 21;27(12):2943-2953. doi: 10.1021/acs.bioconjchem.6b00643.
Leilei Shi 1,  Yi Hu 1,  Ang Lin 2,  Chuan Ma 3,  Chuan Zhang 1,  Yue Su 1,  Linzhu Zhou 1,  Yumei Niu 4,  Xinyuan Zhu 1
Affiliations

Affiliations

  • 1 School of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University , 800 Dongchuan Road, Shanghai 200240, People's Republic of China.
  • 2 Department of Medicine, Immunology and Allergy Unit, Karolinska Institute , Stockholm, SE 17176, Sweden.
  • 3 School of Dental Medicine, Shanghai Jiao Tong University , 227 South Chongqing Road, Shanghai, 200025, P. R. China.
  • 4 Department of Endodontics, The First Affiliated Hospital of Harbin Medical University , 143 Yiman Street, Harbin 150001, P. R. China.
PMID: 27998073 DOI: 10.1021/acs.bioconjchem.6b00643
Abstract

Colorectal Cancer (CRC) is one of the most commonly diagnosed cancers worldwide, especially in developed countries. Although patients' overall survival has been improved by either conventional chemotherapy or newly developed anti-angiogenesis treatment based on its highly vascularized feature, the relatively low therapeutic efficacy and severe side effects remain big problems in clinical practice. In this study, we describe an easy method to construct a novel matrix metalloproteinase-2 (MMP-2) responsive nanocarrier, which can load hydrophobic agents (camptothecin and sorafenib) with high efficiency to exert synergistic efficacy for CRC treatment. The drug-containing nanoparticles can particularly respond to the MMP-2 and realize the controlled release of payloads at the tumor site. Moreover, both in vitro and in vivo studies have demonstrated that this responsive nanoparticle exhibits much higher therapeutic efficacy than that of single antitumor agents or combined drugs coadministrated in traditional ways.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12169
    99.81%, MMP 抑制剂
    MMP
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z